Re-Evaluating Risks and Benefits in Human Subjects Research
By Jonathan Kahn, Biopolitical Times guest contributor
| 05. 25. 2011
Modern bioethics is grounded in four basic principles: respect for persons (i.e. autonomy), beneficence, nonmalificence and justice. In a recent presentation at the 2011 ELSI Congress, "Exploring the ELSI Universe," Malia Fullerton, a professor in the Department of Bioethics & Humanities at the University of Washington School of Medicine, noted that "respect for persons" and "beneficence" have come to be the preeminent values in bioethical review of human subjects studies, particularly in the context of IRB review. Respect for persons typically manifests in a concern for informed consent, and beneficence in a concern for weighing the potential harms and benefits of research. Fullerton argued that a more balanced consideration of the other values, particularly justice and a concern for persons not just in terms of consent but in terms of dignity, needed to be incorporated into such review.
This got me to thinking about these concepts and their deployment in current biomedical research. Beneficence has often been cast in terms of balancing costs and benefits, as though it were simply a utilitarian calculus. However, in the context of...
Related Articles
By George Janes, BioNews | 01.12.2026
A heart attack patient has become the first person to be treated in a clinical trial of an experimental gene therapy, which aims to strengthen blood vessels after coronary bypass surgery.
Coronary artery bypass surgery is performed to treat...
By Staff, ScienceDaily | 01.05.2026
Scientists at UNSW Sydney have developed a new form of CRISPR technology that could make gene therapy safer while also resolving a decades-long debate about how genes are switched off. The research shows that small chemical markers attached to DNA
...
Following a long-standing CGS tradition, we present a selection of our favorite Biopolitical Times posts of the past year.
In 2025, we published up to four posts every month, written by 12 authors (staff, consultants and allies), some in collaboration and one simply credited to CGS.
These titles are presented in chronological order, except for three In Memoriam notices, which follow. Many more posts that are worth your time can be found in the archive. Scroll down and “VIEW...
By Jonathan Matthews, GMWatch | 12.11.2025
In our first article in this series, we investigated the dark PR tactics that have accompanied Colossal Bioscience’s de-extinction disinformation campaign, in which transgenic cloned grey wolves have been showcased to the world as resurrected dire wolves – a...
